NNMT
Nicotinamide N-methyltransferase
Also known as: NNMT_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P40261
- Gene
- NNMT
- Ensembl
- ENSG00000166741
- Chromosome
- 11
- Canonical length
- 264 aa
- Protein class
- Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Cytosol
OverviewNCBI Gene
N-methylation is one method by which drug and other xenobiotic compounds are metabolized by the liver. This gene encodes the protein responsible for this enzymatic activity which uses S-adenosyl methionine as the methyl donor. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
264 residues, UniProt reviewed canonical sequence.
>P40261|NNMT
1 MESGFTSKDT YLSHFNPRDY LEKYYKFGSR HSAESQILKH LLKNLFKIFC LDGVKGDLLI
61 DIGSGPTIYQ LLSACESFKE IVVTDYSDQN LQELEKWLKK EPEAFDWSPV VTYVCDLEGN
121 RVKGPEKEEK LRQAVKQVLK CDVTQSQPLG AVPLPPADCV LSTLCLDAAC PDLPTYCRAL
181 RNLGSLLKPG GFLVIMDALK SSYYMIGEQK FSSLPLGREA VEAAVKEAGY TIEWFEVISQ
241 SYSSTMANNE GLFSLVARKL SRPLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NNMT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 297 nTPM
Expression across tissuesHPA
Tissue
- liver: 297 nTPM
- blood vessel: 61 nTPM
- adipose tissue: 54 nTPM
- gallbladder: 40 nTPM
- urinary bladder: 40 nTPM
- breast: 39 nTPM
Single-cell type
- hepatocytes: 4,376 nCPM
- myosatellite cells: 1,317 nCPM
- fibroblasts: 759 nCPM
- decidual stromal cells: 748 nCPM
- endometrial secretory cells: 625 nCPM
- mesothelial cells: 555 nCPM
Immune cell
- basophil: 0.3 nTPM
- neutrophil: 0.2 nTPM
- naive B-cell: 0.1 nTPM
- plasmacytoid DC: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- medulla oblongata: 8.3 nTPM
- white matter: 6.4 nTPM
- pons: 4.9 nTPM
- cerebral cortex: 4.3 nTPM
- choroid plexus: 4 nTPM
- spinal cord: 3.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.86
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.19
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- methylation
- NAD+ catabolic process
- nicotinamide metabolic process
- nicotinate metabolic process
- positive regulation of gluconeogenesis
- positive regulation of protein deacetylation
Molecular functions
- nicotinamide N-methyltransferase activity
- pyridine N-methyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NNMT as an antibody target. Whether an autoantibody or antibody against NNMT could matter depends on whether native NNMT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NNMT is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NNMT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...